Aiming To Lead A Global Operation? Start In China!
Moving from China president to a CEO, from regional Asia head to a global pharmaceutical president, several recent senior executive appointments have people wondering if China is increasingly becoming the new launch pad for high flyers eyeing a global pharma leadership role.
You may also be interested in...
Novartis’s former head of West China is moving to lead its global cardio-metabolic franchise, while GSK India and Cipla have made key personnel appointments on the manufacturing front.
Already well-funded Chinese venture Ascletis has completed a large Series B to support the commercialization of effective new oral HCV drugs and progress its pipeline, and has not ruled out the possibility of going public in an IPO.
In what appears to be a step towards a gradual shift away from its strict "COVID Zero" policies, China is poised to approve its first mRNA vaccine - in this case developed domestically - and will accelerate the roll-out of COVID-19 vaccinations in general to seniors over 80.